Total Payments
$382,771
2024 Payments
$23,887
Companies
8
Transactions
513
Medicare Patients
2,724
Medicare Billing
$680,426
Payment Breakdown by Category
Other$355,267 (92.8%)
Travel$16,459 (4.3%)
Food & Beverage$5,628 (1.5%)
Consulting$4,941 (1.3%)
Education$291.14 (0.1%)
Research$125.00 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $355,267 | 280 | 92.8% |
| Travel and Lodging | $16,459 | 125 | 4.3% |
| Food and Beverage | $5,628 | 88 | 1.5% |
| Consulting Fee | $4,941 | 5 | 1.3% |
| Education | $291.14 | 13 | 0.1% |
| Unspecified | $125.00 | 1 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Payments by Type
General
$382,646
512 transactions
Research
$125.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $161,012 | 154 | $0 (2023) |
| Lilly USA, LLC | $133,446 | 226 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $71,241 | 102 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $16,807 | 27 | $0 (2017) |
| GlaxoSmithKline, LLC. | $125.00 | 1 | $0 (2017) |
| Corcept Therapeutics | $66.25 | 1 | $0 (2019) |
| Mannkind Corporation | $59.40 | 1 | $0 (2019) |
| Abbott Laboratories | $13.79 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,887 | 43 | Lilly USA, LLC ($23,873) |
| 2023 | $58,617 | 97 | Lilly USA, LLC ($46,071) |
| 2022 | $31,803 | 33 | Novo Nordisk Inc ($21,168) |
| 2021 | $54,792 | 65 | Novo Nordisk Inc ($31,861) |
| 2020 | $52,226 | 79 | Lilly USA, LLC ($28,416) |
| 2019 | $43,282 | 57 | Novo Nordisk Inc ($20,983) |
| 2018 | $48,414 | 44 | Novo Nordisk Inc ($38,440) |
| 2017 | $69,750 | 95 | Novo Nordisk Inc ($28,445) |
All Payment Transactions
513 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 09/23/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $113.90 | General |
| Category: Diabetes | ||||||
| 09/23/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $7.00 | General |
| Category: Diabetes | ||||||
| 09/09/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Diabetes | ||||||
| 09/09/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $875.00 | General |
| Category: Diabetes | ||||||
| 08/01/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 06/26/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: Diabetes Care | ||||||
| 06/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $111.22 | General |
| Category: Diabetes | ||||||
| 06/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $105.19 | General |
| Category: Diabetes | ||||||
| 05/31/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 05/29/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Diabetes | ||||||
| 05/29/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,225.00 | General |
| Category: Diabetes | ||||||
| 05/28/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Diabetes | ||||||
| 05/28/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Diabetes | ||||||
| 05/28/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,225.00 | General |
| Category: Diabetes | ||||||
| 05/24/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Diabetes | ||||||
| 05/22/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $436.62 | General |
| 05/22/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Diabetes | ||||||
| 05/22/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Diabetes | ||||||
| 05/21/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $119.62 | General |
| Category: Diabetes | ||||||
| 05/03/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 04/22/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 03/01/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $17.42 | General |
| Category: Diabetes | ||||||
| 02/29/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 618 | 7,140 | $563,394 | $189,293 |
| 2022 | 9 | 643 | 6,696 | $551,780 | $183,260 |
| 2021 | 8 | 635 | 6,503 | $528,767 | $182,057 |
| 2020 | 12 | 828 | 4,517 | $388,347 | $125,816 |
Total Patients
2,724
Total Services
24,856
Medicare Billing
$680,426
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 57 | 6,180 | $278,100 | $111,826 | 40.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 282 | 514 | $187,096 | $54,564 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 91 | 99 | $24,453 | $7,559 | 30.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $28,808 | $6,706 | 23.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 63 | 132 | $21,384 | $3,929 | 18.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 16 | $7,824 | $2,615 | 33.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 61 | 147 | $15,729 | $2,094 | 13.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 53 | 5,640 | $250,680 | $93,569 | 37.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 273 | 567 | $200,151 | $62,669 | 31.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 63 | 63 | $33,894 | $8,770 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 94 | 105 | $25,200 | $8,187 | 32.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 61 | 136 | $20,944 | $4,250 | 20.3% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2022 | 16 | 38 | $5,092 | $1,732 | 34.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 57 | 114 | $11,970 | $1,609 | 13.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 17 | $2,329 | $1,530 | 65.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 14 | 16 | $1,520 | $944.04 | 62.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 53 | 5,461 | $229,362 | $87,586 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 300 | 613 | $210,259 | $68,279 | 32.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 66 | 66 | $34,452 | $9,516 | 27.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 69 | 78 | $18,174 | $6,600 | 36.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 47 | 117 | $18,018 | $3,701 | 20.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 26 | 41 | $5,453 | $3,528 | 64.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 57 | 105 | $11,025 | $1,507 | 13.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 17 | 22 | $2,024 | $1,340 | 66.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 37 | 3,480 | $146,160 | $52,620 | 36.0% |
About Dr. Todd Kaye, MD
Dr. Todd Kaye, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Mountain View, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295787646.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Todd Kaye, MD has received a total of $382,771 in payments from pharmaceutical and medical device companies, with $23,887 received in 2024. These payments were reported across 513 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($355,267).
As a Medicare-enrolled provider, Kaye has provided services to 2,724 Medicare beneficiaries, totaling 24,856 services with total Medicare billing of $680,426. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Mountain View, CA
- Active Since 05/16/2006
- Last Updated 12/02/2011
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1295787646
Products in Payments
- JARDIANCE (Drug) $135,162
- MOUNJARO (Drug) $66,610
- Ozempic (Drug) $41,752
- Tresiba (Drug) $30,783
- RYBELSUS (Drug) $25,404
- Rybelsus (Drug) $19,897
- Victoza (Drug) $18,094
- INVOKANA (Drug) $16,807
- Xultophy 100/3.6 (Drug) $10,097
- Xultophy (Drug) $220.00
- Korlym (Drug) $66.25
- AFREZZA (Drug) $59.40
- SYNJARDY (Drug) $51.90
- FREESTYLE LIBRE 3 (Device) $13.79
- LYUMJEV (Drug) $5.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Mountain View
Dr. Michael Greenfield, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $17,712
Endocrinology, Diabetes & Metabolism $17,712
Preethi Sridhar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $6,476
Endocrinology, Diabetes & Metabolism $6,476
Leonard Doberne, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $5,505
Endocrinology, Diabetes & Metabolism $5,505
Dr. Sidra Azim, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $4,436
Endocrinology, Diabetes & Metabolism $4,436
Shervin Yousefian, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $4,133
Endocrinology, Diabetes & Metabolism $4,133
Dr. Mariam Manoukian, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $2,047
Endocrinology, Diabetes & Metabolism $2,047